ERBB2 and breast carcinoma: Furthermore, the high rates of pathologic complete response (pCR) following neoadjuvant chemotherapy in HER2-positive breast cancer subtypes raise the question of whether surgery could be safely avoided, especially if the local tumor has been effectively eradicated by neoadjuvant chemotherapy [114].